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Tuberculosis is still a major threat to global health. The disease in humans is caused
by a bacterium, Mycobacterium tuberculosis, and treatment of an infected individual
requires more than six months of chemotherapy. Because such a long course of
treatment is required, compliance is low, which can result in the development of
multidrug resistant strains (MDR-TB) and even extremely resistant strains (XDR-TB).
Identifying new drug targets and potential lead therapeutic compounds are needed
to combat MDR-XDR-TB. We developed a new type of assay based on the
visualization of mycobacterium replication within host cells and applied it for the
search of compounds that are able to chase the pathogen from its hideout. As a
result, we found 20 new series of drug candidates that are effective against the
bacilli in its hiding place, potentially addressing a crucial aspect in the resilience of
the disease. We also showed that one series of compounds acts by inhibiting a key
enzyme required for the synthesis of an essential component from the mycobacterial
cell wall that is not targeted by any of the commercially available antituberculosis
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